logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy set to benefit from Large Hadron Collider spin-off

Dr Michael Sinclair, CEO of Advanced Oncotherapy (LON:AVO), tells Proactive Investors his firm is uniquely placed to exploit a strand of particle physics from the Cern Laboratories to combat cancer tumours. Mike says that AVO is working towards producing proton beam therapy machines, at a fraction of the cost of existing machines, using its own patented technology.

Quick facts: Advanced Oncotherapy PLC

Price: 37.5 GBX

LSE:AVO
Market: LSE
Market Cap: £91.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: VR Education's ENGAGE platform to be included in new 5G VR...

Headlines from the Proactive UK newsroom. VR Education’s (LON:VRE) Engage platform has been chosen as an embedded title in a new 5G virtual reality headset being developed by a consortium of Deutsche Telekom, Qualcomm and XRSPACE. The new headset is due to launch in...

1 week, 3 days ago

RNS

Holding(s) in Company

1 week, 4 days ago

Total Voting Rights

2 weeks, 1 day ago

Holding(s) in Company

2 weeks, 2 days ago

Total Voting Rights

on 6/11/19

Change of Broker

on 10/10/19

Total Voting Rights

on 30/9/19

2 min read